Patents by Inventor Antonio Fontanellas Romá

Antonio Fontanellas Romá has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • POLYNUCLEOTIDES ENCODING PORPHOBILINOGEN DEAMINASE FOR THE TREATMENT OF ACUTE INTERMITTENT PORPHYRIA
    Publication number: 20230112986
    Abstract: The invention relates to mRNA therapy for the treatment of Acute Intermittent Porphyria (AIP). mRNAs for use in the invention, when administered in vivo, encode human porphobilinogen deaminase (PBGD), isoforms thereof, functional fragments thereof, and fusion proteins comprising PBGD. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to affect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of PBGD expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient PBGD activity in subjects, namely porphobilinogen and aminolevulinate (PBG and ALA).
    Type: Application
    Filed: July 21, 2022
    Publication date: April 13, 2023
    Applicants: ModernaTX, Inc., Fundacion Para La Investigacion Medica Aplicada
    Inventors: Paolo MARTINI, Stephen HOGE, Kerry BENENATO, Vladimir PRESNVAK, Lei JIANG, Iain MCFADYEN, Ellalahewage Sathyajith KUMARASINGHE, Antonio FONTANELLAS ROMA, Pedro BERRAONDO LOPEZ, Matias Antonio AVILA ZARAGOZA, Lin Tung GUEY, Staci SABNIS
  • Human porphobilinogen deaminase derived proteins and polynucleotides and uses thereof
    Patent number: 11390854
    Abstract: The present disclosure relates to human porphobilinogen deaminase derived proteins and polynucleotides and methods of using these proteins and polynucleotides.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: July 19, 2022
    Assignee: Fundacion Para la Investigacion Medica Aplicada
    Inventors: Antonio Fontanellas Roma, Irantzu Serrano Mendioroz, Pedro Berraondo Lopez
  • HUMAN PORPHOBILINOGEN DEAMINASE DERIVED PROTEINS AND POLYNUCLEOTIDES AND USES THEREOF
    Publication number: 20210139866
    Abstract: The present disclosure relates to human porphobilinogen deaminase derived proteins and polynucleotides and methods of using these proteins and polynucleotides.
    Type: Application
    Filed: May 18, 2017
    Publication date: May 13, 2021
    Inventors: Antonio Fontanellas ROMA, Irantzu Serrano MENDIOROZ, Pedro Berraondo LOPEZ
  • POLYNUCLEOTIDES ENCODING PORPHOBILINOGEN DEAMINASE FOR THE TREATMENT OF ACUTE INTERMITTENT PORPHYRIA
    Publication number: 20200085916
    Abstract: The invention relates to mRNA therapy for the treatment of Acute Intermittent Porphyria (AIP). mRNAs for use in the invention, when administered in vivo, encode human porphobilinogen deaminase (PBGD), isoforms thereof, functional fragments thereof, and fusion proteins comprising PBGD. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to affect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of PBGD expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient PBGD activity in subjects, namely porphobilinogen and aminolevulinate (PBG and ALA).
    Type: Application
    Filed: May 18, 2017
    Publication date: March 19, 2020
    Inventors: Paolo Martini, Stephen Hoge, Kerry Benenato, Vladimir Presnyak, Lei Jiang, Iain McFadyen, Ellalahewage Sathyajith Kumarasinghe, Antonio Fontanellas Roma, Pedro Berraondo Lopez, Matias Antonio Avila Zaragoza, Lin Tung Guey, Staci Sabnis
  • Porphobilinogen deaminase gene therapy
    Patent number: 8697665
    Abstract: The present invention relates to nucleotide sequences coding for human porphobilinogen deaminase that are optimised for higher expression in mammalian cells. The invention further relates to DNA constructs comprising such optimised synthetic coding sequences for use in gene therapy of conditions caused by a deficiency in porphobilinogen deaminase, such as acute intermittent porphyria. Accordingly, the present invention relates to a nucleic acid or a nucleic acid construct comprising a nucleotide sequence coding for a human porphobilinogen deaminase, wherein at least 320 of the codons coding for the human porphobilinogen deaminase are identical to the codons in SEQ ID NO: 1 or wherein at least 305 of the codons coding for the human porphobilinogen deaminase are identical to the codons in SEQ ID NO: 3.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: April 15, 2014
    Assignees: Proyecto de Biomedicina CIMA S.L., Uniqure Biopharma B.V.
    Inventors: Antonio Fontanellas Romá, Gloria González Aseguinolaza, Maria Sol Rodriguez Pena, Maria Astrid Pañeda Rodriguez, Jaap Twisk, Jesús Maria Prieto Valtueña, Harald Petry, Sander Jan Hendrik Van Deventer
  • PORPHOBILINOGEN DEAMINASE GENE THERAPY
    Publication number: 20110262399
    Abstract: The present invention relates to nucleotide sequences coding for human porphobilinogen deaminase that are optimised for higher expression in mammalian cells. The invention further relates to DNA constructs comprising such optimised synthetic coding sequences for use in gene therapy of conditions caused by a deficiency in porphobilinogen deaminase, such as acute intermittent porphyria. Accordingly, the present invention relates to a nucleic acid or a nucleic acid construct comprising a nucleotide sequence coding for a human porphobilinogen deaminase, wherein at least 320 of the codons coding for the human porphobilinogen deaminase are identical to the codons in SEQ ID NO: 1 or wherein at least 305 of the codons coding for the human porphobilinogen deaminase are identical to the codons in SEQ ID NO: 3.
    Type: Application
    Filed: September 29, 2009
    Publication date: October 27, 2011
    Applicants: Proyecto de Biomedicina CIMA S.L., Amsterdam Molecular Therapeutics (AMT) B.V.
    Inventors: Antonio Fontanellas Romá, Gloria González Aseguinolaza, Maria Sol Rodriguez Pena, Maria Astrid Pañeda Rodriguez, Jaap Twisk, Jesús Maria Prieto Valtueña, Harald Petry, Sander Jan Hendrik Van Deventer